NASDAQ:ALNA - Allena Pharmaceuticals Stock Price, News, & Analysis

Sign in or create an account to add this stock to your watchlist.
$6.91 -0.04 (-0.58 %)
(As of 02/15/2019 04:00 PM ET)
Previous Close$6.91
Today's Range$6.72 - $7.1593
52-Week Range$4.80 - $17.56
Volume45,196 shs
Average Volume33,147 shs
Market Capitalization$143.46 million
P/E Ratio-1.44
Dividend YieldN/A
Beta1.9
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States and internationally. The company's lead product candidate is ALLN-177, an oral enzyme therapeutic for the treatment of enteric hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346 for patients with hyperuricemia and moderate to severe chronic kidney diseases. The company was incorporated in 2011 and is headquartered in Newton, Massachusetts.

Receive ALNA News and Ratings via Email

Sign-up to receive the latest news and ratings for ALNA and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:ALNA
CUSIPN/A
Phone617-467-4577

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.01 per share

Profitability

Net Income$-21,650,000.00

Miscellaneous

Employees34
Market Cap$143.46 million
OptionableNot Optionable

Allena Pharmaceuticals (NASDAQ:ALNA) Frequently Asked Questions

What is Allena Pharmaceuticals' stock symbol?

Allena Pharmaceuticals trades on the NASDAQ under the ticker symbol "ALNA."

How were Allena Pharmaceuticals' earnings last quarter?

Allena Pharmaceuticals Inc (NASDAQ:ALNA) posted its earnings results on Wednesday, November, 7th. The company reported ($0.46) earnings per share for the quarter, beating the Thomson Reuters' consensus estimate of ($0.47) by $0.01. View Allena Pharmaceuticals' Earnings History.

When is Allena Pharmaceuticals' next earnings date?

Allena Pharmaceuticals is scheduled to release their next quarterly earnings announcement on Tuesday, March 26th 2019. View Earnings Estimates for Allena Pharmaceuticals.

What price target have analysts set for ALNA?

8 brokerages have issued 1 year price targets for Allena Pharmaceuticals' stock. Their forecasts range from $20.00 to $61.00. On average, they anticipate Allena Pharmaceuticals' stock price to reach $29.5714 in the next twelve months. This suggests a possible upside of 328.0% from the stock's current price. View Analyst Price Targets for Allena Pharmaceuticals.

What is the consensus analysts' recommendation for Allena Pharmaceuticals?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Allena Pharmaceuticals in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Allena Pharmaceuticals.

What are Wall Street analysts saying about Allena Pharmaceuticals stock?

Here are some recent quotes from research analysts about Allena Pharmaceuticals stock:
  • 1. According to Zacks Investment Research, "Allena Pharmaceuticals, Inc. is a biopharmaceutical company. It engages in developing and commercializing oral enzyme therapeutics to treat patients with rare and severe metabolic and kidney disorders primarily in the United States. The companys product candidate includes ALLN-177 and ALLN-346 which are in clinical stages. Allena Pharmaceuticals, Inc. is headquartered in Newton, Massachusetts. " (1/14/2019)
  • 2. Cowen Inc analysts commented, "We expect SEL-212 to show (1) superior efficacy, (2) better safety, and (3) less frequent dosing vs Krystexxa in the head-to-head study, giving SEL-212 a major commercial advantage." (8/8/2018)

Has Allena Pharmaceuticals been receiving favorable news coverage?

Media headlines about ALNA stock have trended somewhat negative on Saturday, according to InfoTrie. The research group scores the sentiment of press coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Allena Pharmaceuticals earned a media sentiment score of -1.0 on InfoTrie's scale. They also assigned press coverage about the company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an effect on the company's share price in the near term.

Who are some of Allena Pharmaceuticals' key competitors?

Who are Allena Pharmaceuticals' key executives?

Allena Pharmaceuticals' management team includes the folowing people:
  • Dr. Alexey L. Margolin, Co-Founder, CEO & Director (Age 66)
  • Dr. Louis Brenner, Pres & COO (Age 49)
  • Mr. Edward J. Wholihan, CFO and VP of Fin. & Admin. (Age 59)
  • Mr. Robert Gallotto, Co-Founder & Strategic Adviser (Age 54)
  • Mr. Hugh Wight, VP of Technical Operations

When did Allena Pharmaceuticals IPO?

(ALNA) raised $80 million in an initial public offering (IPO) on Thursday, November 2nd 2017. The company issued 5,300,000 shares at a price of $14.00-$16.00 per share. Credit Suisse, Jefferies and Cowen served as the underwriters for the IPO and Wedbush PacGrow was co-manager.

Who are Allena Pharmaceuticals' major shareholders?

Allena Pharmaceuticals' stock is owned by a variety of of retail and institutional investors. Top institutional investors include BlackRock Inc. (2.80%), Sphera Funds Management LTD. (1.66%), Perceptive Advisors LLC (0.64%), Geode Capital Management LLC (0.35%), Squarepoint Ops LLC (0.21%) and Fosun International Ltd (0.14%). Company insiders that own Allena Pharmaceuticals stock include Bessemer Venture Partners Vii and James N Topper. View Institutional Ownership Trends for Allena Pharmaceuticals.

Which major investors are selling Allena Pharmaceuticals stock?

ALNA stock was sold by a variety of institutional investors in the last quarter, including Perceptive Advisors LLC, Bank of New York Mellon Corp and New York State Common Retirement Fund. View Insider Buying and Selling for Allena Pharmaceuticals.

Which major investors are buying Allena Pharmaceuticals stock?

ALNA stock was acquired by a variety of institutional investors in the last quarter, including Sphera Funds Management LTD., Fosun International Ltd, Rhumbline Advisers, Geode Capital Management LLC, BlackRock Inc. and Squarepoint Ops LLC. Company insiders that have bought Allena Pharmaceuticals stock in the last two years include Bessemer Venture Partners Vii and James N Topper. View Insider Buying and Selling for Allena Pharmaceuticals.

How do I buy shares of Allena Pharmaceuticals?

Shares of ALNA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Allena Pharmaceuticals' stock price today?

One share of ALNA stock can currently be purchased for approximately $6.91.

How big of a company is Allena Pharmaceuticals?

Allena Pharmaceuticals has a market capitalization of $143.46 million. The company earns $-21,650,000.00 in net income (profit) each year or ($4.80) on an earnings per share basis. Allena Pharmaceuticals employs 34 workers across the globe.

What is Allena Pharmaceuticals' official website?

The official website for Allena Pharmaceuticals is http://www.allenapharma.com.

How can I contact Allena Pharmaceuticals?

Allena Pharmaceuticals' mailing address is ONE NEWTON EXECUTIVE PARK SUITE 202, NEWTON MA, 02462. The company can be reached via phone at 617-467-4577.


MarketBeat Community Rating for Allena Pharmaceuticals (NASDAQ ALNA)

Community Ranking:  2.4 out of 5 (star star)
Outperform Votes:  113 (Vote Outperform)
Underperform Votes:  119 (Vote Underperform)
Total Votes:  232
MarketBeat's community ratings are surveys of what our community members think about Allena Pharmaceuticals and other stocks. Vote "Outperform" if you believe ALNA will outperform the S&P 500 over the long term. Vote "Underperform" if you believe ALNA will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/16/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel